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INTRODUCTION 
Due to increased life expectancy and optimized medical treatments, there is a clear 
need for novel, innovative approaches in reconstructive urology. The aim of tissue 
engineering (TE) reconstruction is to improve the postoperative functional outcome 
using customized natural materials to support the regenerative aspect of the healing 
process. Key factors which are identified for an optimal biological material are 
proper scaffold construction and proper regeneration of the urothelium and smooth 
muscle layers [Drewa, 2015]. The engineered scaffold aims to replace the 
extracellular matrix (ECM), support cell growth and expansion, and provide a 
mechanical and functional structure to replace and incorporate the native tissue. For 
long-term success, the scaffold should be resorbable or autologous to prevent foreign 
body reactions (FBR) that could lead to scarring [Atala, 2012]. However, the ideal 
matrix has not yet been identified, and it remains questionable whether there is a 
matrix that is suitable for the reconstruction of the entire urinary tract. 
Another important question in TE reconstruction is why we have not seen more 
materials in clinical practice. The possible answer is that the main problem is the 
long transfer time and the diverse preclinical knowledge, starting with cell culture 
and in vitro studies, then in vivo animal models leading to clinical trials and 
commercialization, with regulatory oversight at all stages [Ram-Liebig, 2015]. The 
introduction of new surgical methods, innovations or variations does not yet follow 
clear standardized paradigms. Innovation, Development, Exploration, Assessment 
and Long-term Study (IDEAL) is a new reporting approach, introduced by an 
international panel of surgeons, researchers, editors, statisticians and other 
stakeholders who were committed to the production, dissemination and evaluation of 
quality research in surgery [McCulloch, 2009]. Recently, IDEAL stages have been 
adapted for devices (IDEAL-D) as well (see Table 1) to provide clear stages of 
surgical innovation which make it possible to assign all research to its particular level 
of development and evidence [Sedrakyan, 2016].  
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Table 1. Stages of the IDEAL-D framework 
Primary outcome Study design Patients 
Stage 0  Preclinical Concept, safety 
Experimental 
studies (animal, 
cadaver) 
  
Stage 1 
Idea 
“First in 
human”  Innovation 
Case report, case 
series, registration 
Single to 
few (<10) 
Stage 2 
Developmen
t and 
Exploration 
“Tinkering
” with 
device, few 
adopters 
Development, 
safety, efficacy 
Prospective cohort 
trials 10–100 
Stage 3 
Assessment  
Stable 
procedure 
Compare to 
standard, clinical 
outcome 
Randomized 
controlled trial or 
similar 
>100 
Stage 4 
Long term 
Registry, 
long-term 
evaluation 
Quality assurance, 
identification of 
risk factors, 
comparators  
Registry >100 
 
GOALS 
The composition of the ECM of human amniotic membrane (HAM) is similar to that 
of the basement membrane in the urinary tract. Today, HAM allografts are used for 
reconstruction in eye and oral surgery and as dressings in burn patients. Therefore, 
our main goal was to prove that amniotic tissue can be an appropriate scaffold for 
reconstructive techniques in the urinary tract. We aimed to develop a standardized 
and manufacturer-independent process for amnion graft preparation, ensuring 
sterilization while keeping the ECM intact. Moreover, we aimed to ensure that the 
grafts provide feasible materials for surgical practice. Having achieved these goals, 
we conducted in vivo experiments, and, finally, we investigated the possibility of 
transferring experimental results into clinical practice following the steps in the 
IDEAL-D framework. 
Study I. The main purpose was to develop an in vitro approach for amnion 
preparation and to preserve ECM integrity. Different mono- and multilayer 
techniques were tested to achieve a perfect hold and processing of HAM. 
Study II. We aimed to investigate the possibility of bladder and colon grafting and 
the immunogenicity of processed HAM xenografts in vivo. Histological analyses 
were performed to investigate the degradation of HAM and graft rejection and the 
ingrowths of surrounding tissue 7, 21 and 42 days after the implantation. 
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The goal of Study III was to translate the in vivo animal results into a clinical 
scenario. HAM allografts were used to treat human vesico-vaginal fistulas and a case 
of a chronic wound with an entero-cutaneous fistula. The patients were followed up 
in a registry for one year. 
MATERIALS AND METHODS 
In vitro and in vivo experiments 
HAMs were obtained after elective Caesarean sections and informed consent from 
the patients. The amnion was detached from the chorion by mechanical traction, and 
the separated amniotic membranes were cut into 5x5 cm segments. The HAMs were 
fixed to a sterile silicon scaffold and frozen at -20°C for 24h until further use. (Pilot 
studies have shown that storage for up to six months does not cause degradation.) For 
further processing, the HAMs were thawed, sterilized in a 0.25% peracetic acid–
alcohol mixture and incubated for 2h. Various HAM layers were tested to achieve 
the best processing with the possibility to cut and suture.  
Fresh HAM (fHAM) and processed (frozen, sterilized and dried) HAM (pHAM) 
samples were sectioned and stained with H&E according to standard protocols for 
the in vitro studies. The tissues were stained for Ki-67 using rabbit primary 
antibodies to determine cell proliferation.  
48 male Sprague Dawley rats were used at the Institute for Surgical Research of the 
University of Szeged, Hungary (license number V./146/2013) for the in vivo 
experiments. The rats were anaesthetized with 40 mg/kg 10% ketamine, a midline 
laparotomy was performed, and the bladder pressure was evaluated with the 
cystometric method developed by Lundbeck et al. Subsequently, a defined 0.5 cm 
lesion was cut at the bladder dome. In the second group, a defined 0.5 cm length of 
the caecum wall was resected. In the treated amnion groups (bladder n=18 and colon 
n=18), a multilayer amnion patch was trimmed to cover the defect size (10x10 mm) 
and was fixed to the bladder or colon wall with 6-0 Monocryl single sutures at 3–4 
points. Additional human fibrin glue was used to seal the lesion. In the first control 
group (B1, n=6 and C1, n=6), the defect was closed with a single Monocryl 6-0 
running suture and fibrin glue. In the second control group (B2, n=3 and C2, n=3), 
the amnion graft was sutured to the bladder or colon wall without a prior lesion. The 
animals were sacrificed at one week (Ba and Ca, n=10; B1 and C1, n=4; B2 and C2, 
n=2), three weeks (Ba and Ca, n=12; B1 and C1, n=4; B2 and C2, n=2) and six 
weeks (Ba and Ca, n=10; B1 and C1, n=4; B2 and C2, n=2) after surgery. Bladder 
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capacity was determined again, and tissue samples (urinary bladder or colon, kidneys 
and spleen) were collected. HAM grafts, colon and bladder wall reactions were 
assessed, abscess and adhesion formation was recorded, and the area was graded 
semiquantitatively between 0 and 3 according to the van der Ham score [van der 
Ham, 1992]. Deparaffinized sections (5 µm) were used for histology, and the tissue 
architecture and cell infiltration were visualized with H&E staining. For 
immunohistochemistry, tissue sections were deparaffinized, rehydrated and subjected 
to a heat-induced antigen retrieval (citrate buffer, pH 6.0), followed by 3% hydrogen 
peroxide and avidin-biotin blocking. Prior to incubation with the primary antiserum, 
sections were incubated with a PBS blocking solution containing 10% normal horse 
serum, 0.1% bovine serum albumin, 0.05% thimerosal, 0.01% NaN3 and 1% Triton 
X-100. Primary and secondary antisera were diluted in a blocking solution without 
Triton X-100. Sections were incubated overnight with the primary antibody and 
immunostained with the streptavidin–biotin peroxidase method, followed by a 
diaminobenzidine (DAB) chromogen solution. Finally, sections were counterstained 
with haematoxylin. Negative controls were incubated in a blocking solution without 
primary antibodies. Digital images of H&E and α-actin were used for the evaluation 
of smooth muscle content within the reconstructed wall. Pictures were taken using a 
Zeiss Axiophot microscope equipped with an Olympus DP70 digital camera at 4x 
magnification. HAM thickness was measured (in µm), with particular attention paid 
to the transition zone between the amnion graft and the normal bladder or colon wall. 
A semiquantitative score from 0 to 3 for inflammation and from 0 to 2 for 
vascularization was used. Inflammation of the implant region was scored by counting 
lymphocytes in ten fields of 0.25 mm2 in three observer-randomized H&E-stained 
slides (0= <5% cells/field; 1= 5–25%; 2= 25-50%; 3= >50%; 200x magnification). A 
similar score was used for vascularization (0= 0 vessels/mm², 1= 1-3 v/mm²; 2= 
>3v/mm²; 200x magnification). Kidney and spleen specimens were analysed for 
signs of transplant rejection. 
Clinical studies 
I. A 64-year-old female was admitted to the Department of Urology, Lukas Hospital 
Neuss, Germany, with sigma diverticulitis and a chronic vesico-vaginal fistula 
(VVF). She had a previous history of cervical cancer and radio-chemotherapy for 
anal cancer with complete remission. The VVF persisted after multiple abdominal 
operations, and the patient suffered from permanent incontinence and a local skin 
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infection. After a recovery period of three months, we re-evaluated the patient with 
cystography, cystoscopy, ureteropyelography and a vaginal examination. A complex 
vesico-vaginal fistula of 1.5 cm was detected at the apical anterior vaginal wall 
leading to the bladder base. Additionally, scarring of the vagina and distal ureters 
was found, and the patient suffered from a persistent MRSA colonization of the 
urine. Due to the complex situation, it was decided that an individualized treatment 
would be used with off-label use of HAM. Prior to surgery, three layers of HAM 
were fixed with a 4-0 Monocryl suture, and a multilayer HAM of 4 cm was used as a 
graft to close the defect at the edges of the normal bladder wall. 
II. An 83-year-old female underwent a radical cystectomy with a cutaneous 
ureterostomy for locally invasive bladder cancer at the Department of Urology, 
Lukas Hospital Neuss, Germany. Two weeks after surgery, she was admitted again 
with a severe infection of the laparotomy wound. A wide resection of subcutaneous 
tissue with vacuum sealing was necessary, followed by displacement plastic skin 
repair. Seven days later, the patient presented with a cutaneous fistula with purulent 
secretion and communication with a small bowel loop. Two layers of amnion 
dressing were applied weekly after cleaning and debridement for four weeks. The 
wound size was documented, and a biopsy at the wound margin was performed at 
week four.  
Statistics 
Data from different experimental groups were compared using the Mann-Whitney U 
test and the Kruskal-Wallis test. Data are presented as medians with ranges or means 
with standard deviation (SD). P values <0.05 were considered significant. 
RESULTS 
In vitro experiments  
Processed pHAMs were compared with fresh tissues by histology using H&E 
staining. pHAM maintained tissue thickness and structural integrity on a comparable 
level with the amniotic layer of fresh tissue. However, neither fresh amnion nor 
pHAM displayed any positive staining for Ki-67. For the best hold, 4-0, 5-0 and 6-0 
Monocryl sutures were used at 3-4 points to fix the HAM to the scaffold. 
In vivo studies – bladder reconstruction with amnion xenografts 
Two animals (11%) died in the treated group: one due to postoperative sepsis, 
another during anaesthesia. No animals were lost from the control groups. No other 
complications higher than grade II (Clavien–Dindo classification) were observed 
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[Clavien, 2009]. The bladder capacity did not change in the treated group but 
decreased significantly in control group B1 with the suture of the lesion (p=0.01).  
No signs of severe inflammation were found in the abdominal cavity during 
reoperation. Meso-adhesions to the HAM graft were detected in most of the treated 
cases. HAM appeared as a thick, oedematous graft with inflammation running from 
the middle towards the transition zone of the bladder wall at day 7. At days 21 and 
42, HAM was still well defined, albeit with reduced inflammation. Adhesions were 
present in some cases. Inflammation was less prominent in the control groups. 
The xenotransplanted HAM graft covered the bladder wall and maintained its 
architecture at day 7. The lesions could be recognized as regions without smooth 
muscle cells but with abundant connective tissue and signs of inflammation. 
Significant inflammation and an increased number of blood vessels were observed in 
the amnion and between the amnion and the adventitia of the bladder, resulting in an 
enlarged amnion. Infiltrated lymphocytes agglomerated mostly in the area bordering 
the HAM. At day 21, the amnion appeared less thick, and the inflammation was 
significantly diminished (p<0.05). New capillaries started to grow into the 
surrounding connective tissues, and scattered smooth muscle cells emerged in the 
area of the lesion. In the control groups, signs of inflammation had mostly 
disappeared. At day 42, it became more difficult to discern the region of the lesion, 
where the amnion formed a thinner layer on the bladder wall with no signs of 
degradation. Inflammation was markedly reduced in the amnion and in the zone 
between the amnion and the bladder wall (p<0.05). The number of large vessels in 
the amnion appeared to be reduced and periamniotic vascularization increased, but 
these results were not significant. Connective tissue, bundles and thin muscle layers 
were found in abundance in all groups. Smooth muscle regeneration occurred more 
rapidly in the amnion group, although the difference in the regeneration compared to 
the control group with the suture of the lesion was not significant (p<0.05). 
In vivo colon reconstruction with amnion xenograft 
During reoperation, the HAM appeared as a thick oedematous graft with signs of 
inflammation, but severe inflammation was not found in the abdominal cavity. The 
inflammation was less severe in the control groups. Strong adhesions of the HAM 
graft to the small bowel and abdominal wall that withstood tractions were detected in 
most of the treated cases. At day 7, a higher adhesion score with a larger coverage 
area was found in the amnion group (1.8±0.45) vs. group C1 (0.5±0.7) (p<0.05). 
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However, similar adhesion scores were present in groups C1 and C2. At day 21, the 
adhesion score was higher in the amnion group (1.8±0.84) vs. group C1 (1±0) 
(p=0.178), but the difference was statistically not significant. HAM could not be 
identified and in some cases could not be detected at day 42. The adhesions increased 
in the amnion group vs. groups C1 and C2 (p=0.052). 
At day 7, strong inflammation with abundantly increased numbers of lymphocytes 
and blood vessels was observed in the amnion layers and between the amnion and 
the submucosa of the colon, which resulted in an enlarged amnion. A lower-level, 
but still strong inflammation was found in control groups C1 and C2. HAM thickness 
was reduced, and the inflammation was significantly decreased (p<0.05) at days 21 
and 42. Connective tissue bundles and scattered smooth muscle cells appeared in the 
area of the lesion. In control group C1, signs of inflammation (the presence of 
lymphocytes) had mostly disappeared, and there were also no clear signs of 
regeneration of smooth cells in the lesion region. At day 42, it became more difficult 
to verify the presence of the amnion in the treated group, and the different layers of 
the amnion could no longer be distinguished. The amnion, which was significantly 
reduced in thickness, formed a thinner layer on the colon wall. In the control group 
without lesions (C2), the amnion was completely degraded and could no longer be 
detected. Inflammation was markedly reduced in the amnion and in the zone between 
the amnion and the colon wall, but it was still significantly higher compared to 
control group C1 (p<0.05). Despite the presence of scattered smooth muscle cells 
and bundles, it was difficult to measure if there was a clear regeneration of smooth 
muscle compared to control group C1. 
No macroscopic signs of rejection were found in the kidney and spleen specimens. 
However, four out of six animals in the treated group showed an affected kidney at 
day 21. To rule out an obstruction or increased bladder pressure as the cause of these 
findings, we compared the results with the colon study, and the same results were 
demonstrated. The changes were subtle with slightly enlarged tubuli and a slightly 
enlarged urinary space, the glomeruli appeared denser, and no presence of immune 
cells or other signs of transplant rejection were found. At day 42, the kidneys of two 
out of five animals were still slightly affected, whereas no such changes were 
detected in the controls. On the whole, this suggests that a transient, subtle transplant 
glomerulitis was present in the rats with HAM grafts. 
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Clinical cases - vesico-vaginal fistula 
Seven days after surgery, a cystography was performed, and no leakage was present. 
In the next three months, re-evaluations with cystography, cystoscopy and a vaginal 
examination were performed, no recurrent fistula was found, and full recovery of the 
vaginal epithelium was present. The ureter stents were internalized, and the patient 
was able to micturate without incontinence. The bladder capacity was restored to a 
volume of 250 ml. No severe complications and no signs of graft rejection were 
observed over a period of six months. The MRSA colonization in the urine was 
successfully eradicated. However, during the follow-up at ten months, the patient 
reported vaginal urine leakage again and a recurrent fistula was observed at the 
margin of the amnion graft.  
Treatment of an entero-cutaneous fistula 
The wound size was 3x2x1 cm when the HAM was applied. After two weeks, the 
secretion stopped, and the ulcer was reduced by 20% and then healed after eight 
weeks with four applications of HAM. The healing was complete after six-month and 
nine-month follow-ups. Histological analysis showed re-epithelialization and 
recovery of muscle cells four weeks after the treatment. The HAM did not degrade 
and could still be detected as a smooth layer on the surface. Moderate inflammation 
was present, but signs of graft rejection were not observed.  
DISCUSSION 
There are several methods for amnion preparation, but none of them has been 
compared properly or standardized. For clinical use, HAMs should be intact and free 
from contamination. HAM is sterile when collected during a Caesarean section 
[Adds, 2001], but sterilization is still recommended to avoid the risk of infection. 
Cryopreserved, dried, irradiated or freeze-dried amniotic tissues have already been 
used in previous studies. In our experiments, amniotic membranes were stored at -
20°C with PBS to produce a safe, effective and minimally manipulated tissue. A 
0.25% peracetic acid and ethanol mixture was used for sterilization, a procedure 
proven to be reliable for preserving ECM and accepted by the Paul Ehrlich Institute 
[Pruss, 2001]. HAM is fragile and must be handled with care to avoid tearing and 
rolling, so for this reason, dried HAMs were fixed by suture to a sterile silicon 
scaffold. Next, we used several layers of HAM to provide better handling and more 
stability for the next steps of the planned tissue reconstruction. 
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Urinary tract reconstruction with amniotic tissue 
HAMs were used in urology in 1955 for the reconstruction of the urethra [Lenko, 
1955]. However, only a few successful attempts have been reported to date. Long 
ureteral wall strictures (5.5 cm) were supplemented by using folded HAM allografts, 
and good results were reported after an average follow-up period of 25.2 months 
[Koziak, 2007]. Brandt and his colleagues successfully reconstructed a female 
urethra using autologous grafts prepared from HAM [Brandt, 2000]. Adamowicz et 
al. designed a sandwich-structured biocomposite material from a frozen cell-seeded 
(i.e. bone marrow-derived mesenchymal stem cells) membrane covered on both sides 
with two-layered membranes prepared from electrospun poly-(L-lactide-co-ε-
caprolactone) (PLCL). The authors considered this reinforcement of the AM 
necessary because of its poor mechanical qualities. The new biomaterial (10x10 mm) 
was used for bladder augmentation after hemicystectomy in rats [Adamowicz, 
2016]. Immunohistochemical analysis showed effective regeneration of the urothelial 
and smooth muscle cells and complete PLCL degradation. However, the authors 
reported a moderate inflammatory reaction after three months. Our results confirmed 
these previous reports. In our study, no signs of leakage or unchanged bladder 
capacity were observed after reconstruction. The inflammatory reaction had already 
almost disappeared after six weeks. It should be added that larger grafts require 
sufficient nutrition of the cells and removal of waste products to eliminate/reduce the 
risk of fibrosis and shrinkage. With a diffusion distance from the supplying blood 
vessel of ~150–200 µm, HAMs efficiently conduct sufficient oxygenation [Laschke, 
2006]. HAM also acts as a basal membrane and thus facilitates the migration and 
enhanced adhesion of the epithelial cells [Sonnenberg, 1991]. Although we expected 
a faster regeneration of smooth muscles, the regeneration could not be evaluated in a 
standardized way due to the smaller size of the grafts and an overlap with the normal 
bladder wall. Nevertheless, no signs of graft shrinkage or necrosis were found over a 
six-week period. We had success using the unseeded amniotic membranes in a three- 
to four-layer technique. Incorporation of autologous urothelial and smooth muscle 
cells involves a costly and time-consuming process of cell harvesting, culturing and 
seeding. Furthermore, cells from diseased bladders may behave differently from 
normal cells, rendering their use for tissue engineering applications questionable 
[Roelofs, 2016]. In addition, there are some data that show that scaffolds without 
seeded urothelial cells perform better than those with seeded cells [Engel, 2014]. The 
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limitation of our study is the relatively small size of the grafts (10x10 mm) and the 
relatively short follow-up period. The process of regeneration in larger constructs 
and damaged tissue conditions also needs to be evaluated.  
Bowel tract reconstruction with the amniotic tissue 
Adhesions are key problems in the peritoneal cavity following surgeries 
[Brochhausen, 2011]. Several strategies have been proposed for the prevention of 
adhesion formation, including the use of allogenic (e.g. peritoneum), xenologous 
materials (e.g. collagen), synthetic materials (e.g. polymers) and sealants (fibrin), but 
the optimal method has not yet been identified and translated into clinical practice. 
We aimed to prove that HAM can prevent adhesion formation in bowel surgery. For 
this purpose, we designed a rodent model of anastomosis leakage and repair of small 
defects in the caecum. The results demonstrated that the use of amniotic membranes 
for the repair of bowel lesions is not beneficial in a xenograft model as compared to a 
standard therapy. We did not find clinical signs of rejection, but we did observe 
adhesions and the presence of inflammatory reaction in the HAM-treated group. 
(89% in the treated group vs. 33% in the control group, p<0.05). Moreover, the 
severity of inflammatory reactions was significantly higher in the amnion-treated 
group, probably due to insufficient bowel sealing with the graft. Similarly, an 
increased number of inflammatory cells was reported by other groups after the 
application of HAM in rodent models [Uludag, 2009].  
Only a few reports are available to date on the use of HAMs in reconstructive bowel 
surgery [Schimidt, 2010]. Several studies have shown the degradation of the ECM 
components from bacterial-derived metalloproteases in the colon [Pasternak, 2010; 
Shogan, 2015]. If applied as a graft, a rapid degradation of the amnion occurs 
between days 14 and 90, depending on the grafted tissue and number of layers 
[Kesting, 2008; Schimidt, 2010]. In our study, the transformation of multilayer 
HAMs, tissue reorganization and degradation were observed between days 21 and 
42. We used fibrin glue as well, though no effects of fibrin glue on adhesion 
formation have previously been reported [Kanellos, 2006]. Another limitation of our 
model was the healthy animal population. A peritonitis model, as proposed by 
several groups, could be more appropriate to clarify the protective role of HAM on 
the anastomosis line [Wichtermann, 1980]. In a rat model of colon anastomosis 
where the caecum was covered with a 10 mm amnion wrap, the leakage rate was as 
high as 25% after seven days in the standard anastomosis group vs. 0% in the amnion 
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group [Uludag, 2009]. Unlike in our model, the authors reported a high dehiscence 
rate of 40–50% in the control group with standard anastomosis. The difference is 
probably due to the different experimental design. In our study, no signs of 
dehiscence were detected in the control group with the suture of a small bowel wall 
defect. However, the increased initial inflammation and adhesions in the amnion 
group appear to be a sign of insufficient bowel sealing with an amnion graft. This 
notion is supported by the finding that one case of postoperative peritonitis and 
sepsis was detected in the HAM group.  
In conclusion, we suggest that HAMs alone are not suitable barriers to preventing 
adhesions and inflammation, and therefore this technique is not useful or superior to 
a standard suture for the reconstruction of the bowel wall in a xenograft model. 
However, the anastomosis-protective potential of HAM use in a high-risk situation 
(e.g. peritonitis model) needs to be evaluated further. Other limitations of our study 
were the rather small size of the grafts (10x10 mm), the short follow-up, the small 
sample size and the xenograft model itself. Nevertheless, it should be added that a 
smaller number of elements was purposefully planned as is the case with proof-of-
principle studies.  
The xenograft animal model and the IDEAL recommendations 
Rodents are employed as standard cost-effective models for most preclinical trials. 
We first conducted animal experiments to clarify the possibility of graft rejection in a 
xenograft rodent model and the applicability of HAM as a future biomaterial in 
accordance with the IDEAL-D recommendations. No clinical signs of rejection were 
detected, although a transient inflammatory reaction was seen in the amniotic and 
periamniotic tissue. A similar transient increase in inflammatory cells was reported 
in the case of cryopreserved HAMs for soft tissue repair in rats [Kesting, 2008]. 
Additionally, most animals in the amnion group presented a subtle acellular 
transplant glomerulitis. These changes can be classified as borderline mild acute 
rejection according to the Banff classification [Bhowmik, 2010]. It is likely that the 
glomerulitis was due to the xenologous model and would not develop in an allograft. 
This notion is supported by the fact that HAMs in human patients did not induce 
inflammation and graft rejection; the grafts were well-tolerated without side-effects. 
Nevertheless, future studies should test different HAM-grafting techniques in animal 
models of peritonitis and fistulas to simulate the outcome in humans.  
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HAM-assisted repair of a vesico-vaginal fistula 
Complex vesico-vaginal fistulas usually present a poor outcome with high recurrence 
rates and a devastating clinical course. Radiation-induced recurrent vesico-vaginal 
fistulas have the lowest success rate and require the most demanding interventions 
[Ghoniem, 2014]. Vascularization of the graft or flap is the main requirement for 
successful healing. In our case, HAM was used as a sealing onlay graft and only 
served as a transient seal in a damaged radiated tissue in a patient with a recurrent 
fistula ten months after the initial surgery. There is only one published report on 
VVF repair with an amniotic membrane allograft in an irradiated field with a robotic 
procedure [Price, 2016]. The vaginal and bladder fistula defects were closed 
separately in two layers using interrupted 4-0 polydixanone sutures. A rehydrated 
amniotic membrane patch was used as an interposition graft between the vaginal wall 
and bladder and was sutured in place over the surface of the vaginal side. However, 
the follow-up was shorter, only five months. In addition, the processing of the 
amnion allograft was different [Koob, 2014]. A potential problem with the 
dehydrated allograft is the unknown duration of the angiogenic effect, and thus 
patients with radiation fistulas remain at risk for recurrent fistulas for years [Price, 
2016]. Further, well-documented clinical trials are needed that share experience with 
the technique and handling HAM to shed light on the potential value of HAM for the 
treatment of VVF. Due to the rare condition, it is important that every case should be 
registered and reported (IDEAL Stage 1). 
HAM dressing for the treatment of chronic wounds 
Amnion can act as a physical barrier against bacterial contamination and can also 
create a moist environment for healing [Mao, 2016]. Dehydrated amniotic membrane 
and chorion (dHACM) have been used in randomized trials for the treatment of 
chronic diabetic foot ulcera (DFU) [Laurent, 2017]. In a prospective, randomized, 
single-centre clinical trial, wound reduction and rates of complete healing were 
investigated in patients with DFU treated with dHACM versus standard care, and 
significant differences were observed in wound reduction at four and six weeks 
[Zelen, 2013]. Another prospective randomized trial of 40 patients with chronic 
DFUs reported an average time of 2.4 weeks until complete healing [Zelen, 2014]. 
However, most of the studies analysed the use of HAM and HACM in clinically 
uninfected cases. Only one randomized study used a tissue-engineered form of 
wound dressing containing acellular human amniotic collagen membrane vs. wet 
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dressing in patients with partially infected wounds. The complete healing rate was 
significantly higher for the amnion group (40.7% vs. control group, 16.7%) 
[Mohajeri-Tehrani, 2016]. We were the first to report on the successful treatment of 
an entero-cutaneous fistula and infected wound with HAM. In our case, the external 
dressings were changed every two days due to the initial infection of the wound. 
HAM is simple to use and makes it possible to cover larger and irregular wound 
areas as well as deep tunnelling wounds. Future studies in larger numbers of patients 
with infected wounds should be conducted, and inclusion of amnion dressings in the 
algorithm of secondary wound care should also be evaluated. However, the results 
suggest that HAM can be a cost-effective treatment for chronic wounds and can 
reduce hospitalization time. 
The project with regard to the IDEAL-D recommendations  
The protection of intellectual property should be regulated by the authorities at the 
early stages of development [Sedrakyan, 2016]. Animal experiments represent safe 
opportunities to optimize reconstructive techniques with HAM, but results from 
animal or cadaveric studies cannot be directly translated to human studies and should 
be considered as preliminary models for the biological performance of implant 
materials (i.e. IDEAL-D Stage 0). In our case, a functionally useful description of the 
use of HAMs was presented for the repair of VVF and entero-cutaneous fistulas (i.e. 
IDEAL-D Stage 1). This procedure should prevent surgeons and researchers from 
repeating a harmful error reported by another investigator and bundling the 
knowledge. With the next step, prospective and quasi-randomized clinical 
development studies (Stage 2) with the application of HAM for ureteral 
reconstruction, protection of the urethra anastomosis and repair of fistula conditions 
in the urinary tract can be planned. These studies will be able to describe the 
technical modifications in surgical procedures and establish a consensus among 
surgical teams (n<100). At this stage, the technique is performed by the investigator 
and a few other innovators, with approval by regulatory authorities as the aim. The 
main outcome criteria and complications should be identified and reported using a 
validated classification. If possible, randomized trials are required at IDEAL Stage 3. 
Data should be included in a registry at an early stage to uniquely identify the 
patient, to enable surgeons to track outcomes and adverse events and to vet findings 
from smaller observational studies (Stages 2–4). Our research group used an 
international registry and our own web-based one [Agha, 2017; Barski, Int J Surg 
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2017]. The main problem at this stage is the challenging technical requirements for 
producing TE materials. Manufacturing sites inspected according to the principles of 
Good Manufacturing Practice are required. Such issues become even more 
challenging when seeded matrices are used. In Europe, the process is constrained 
further by regulatory challenges because of legislation in individual countries within 
the EU that are regulated by the European Medicines Agency [Ram-Liebig, 2015; 
Sievert, 2017]. We need a safe regulatory system that does not hinder innovation 
unnecessarily and encourages the production of adequate valid evidence of safety 
and efficacy. IDEAL-D could provide a framework for the regulation of TE studies 
and innovation in the future.  
 
SUMMARY OF THE NEW FINDINGS 
The development of this surgical device (i.e. the use of HAM in reconstructive 
urology) strictly followed the IDEAL-D recommendations at every step to ensure 
comparability and transparency. 
1. A sterilization process was developed for HAM, and a method was designed to 
achieve stability and better handling during surgery. Several layers of HAM were 
attached to a silicon scaffold, and histological evidence was provided that the ECM 
structure and collagen composition were preserved during the processing method. 
2. Unseeded HAM grafts were used for the in vivo reconstruction of the urinary 
bladder in a short-term xenograft study. No signs of graft shrinkage or necrosis were 
demonstrated during a six-week follow-up period and only a minimal immunological 
reaction developed. The functional and histological results demonstrated the 
suitability of HAM for the reconstruction of the rat urinary tract. 
3. The unseeded HAMs increased the adhesion formation and were not suitable for 
the repair of bowel defects in rats. HAM grafts are not indicated for the 
reconstruction of the bowel wall. The anastomosis-protective property of HAM in 
high-risk situations (e.g. peritonitis models) needs further evaluation. 
4. We demonstrated the possibilities for the transient use of HAM in clinical practice 
as sealing onlay grafts in a complex vesico-vaginal fistula case. 
5. We demonstrated that an entero-cutaneous fistula with an infected wound can be 
successfully treated with several HAM dressings. The use of HAM allowed for the 
coverage of large and irregular surface areas and deep tunnelling wounds. This 
suggests that HAM can be a useful, potential scaffold for reconstruction surgeries. 
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